Pyrrolidine dithiocarbamate reduces vascular prostanoid-induced responses in aged type 2 diabetic rat model

Journal of Pharmacological Sciences

Volumn 110, Issue 3, 2009, Pages 326-333

  Matsumoto, Takayuki ^a   Ishida, Keiko ^a   Kobayashi, Tsuneo ^a   Kamata, Katsuo ^a  

^a HOSHI UNIVERSITY   (Japan)

Author keywords

Diabetes; Endothelium derived contracting factor (EDCF); Nuclear factor B (NF B); Prostanoid; Pyrrolidine dithiocarbamate (PDTC)

Indexed keywords

ACETYLCHOLINE; ARACHIDONIC ACID; ENDOTHELIUM DERIVED CONSTRICTING FACTOR; NITRATE; NITRIC OXIDE; NITRITE; PROSTAGLANDIN E2; PROSTANOID; PYRROLIDINE DITHIOCARBAMATE;

AGED; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA; ARTERY CONSTRICTION; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; PARAMETER; RAT; RAT STRAIN;

EID: 67749142092     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.09116FP     Document Type: Article

References (53)

1. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature. 2001;414:813-820. (Pubitemid 34000785)
2. Sheetz MJ, King GL. Molecular understanding of hyperglycemia's adverse effects for diabetic complications. JAMA. 2002;288:2579-2588.
3. Shinozaki K, Ayajiki K, Kashiwagi A, Masada M, Okamura T. Malfunction of vascular control in lifestyle-related diseases: mechanisms underlying endothelial dysfunction in the insulinresistant state. J Pharmacol Sci. 2004;96:401-405. (Pubitemid 40144059)
4. Kamata K, Miyata N, Kasuya Y. Impairment of endotheliumdependent relaxation and changes in levels of cyclic GMP in aorta from streptozotocin-induced diabetic rats. Br J Pharmacol. 1989;97:614-618. (Pubitemid 19142769)
5. Hattori Y, Kawasaki H, Abe K, Kanno M. Superoxide dismutase recovers altered endothelium-dependent relaxation in diabetic rat aorta. Am J Physiol. 1991;261:H1086-H1094.
6. Poston L, Taylor PD, Glaxo/MRS Young Investigator Prize. Endothelium-mediated vascular function in insulin-dependent diabetes mellitus. Clin Sci. 1995;88:245-255.
7. Pieper GM. Review of alterations in endothelial nitric oxide production in diabetes: protective role of arginine on endothelial dysfunction. Hypertension. 1998;31:1047-1060.
8. De Vriese AS, Verbeuren TJ, Van de Voorde J, Lameire NH, Vanhoutte PM. Endothelial dysfunction in diabetes. Br J Pharmacol. 2000;130:963-974.
9. Cohen RA. Role of nitric oxide in diabetic complications. Am J Ther. 2005;12:499-502. (Pubitemid 41689750)
10. Takenouchi Y, Kobayashi T, Matsumoto T, Kamata K. Possible involvement of Akt activity in endothelial dysfunction in type 2 diabetic mice. J Pharmacol Sci. 2008;106:600-608. (Pubitemid 351556239)
11. Cosentino F, Eto M, De Paolis P, van der Loo B, Bachschmid M, Ullrich V, et al. High glucose causes upregulation of cyclooxygenase-2 and alters prostanoid profile in human endothelial cells: role of protein kinase C and reactive oxygen species. Circulation. 2003;107:1017-1023. (Pubitemid 36258726)
12. Bagi Z, Erdei N, Toth A, Li W, Hintze TH, Koller A, et al. Type 2 diabetic mice have increased arteriolar tone and blood pressure: enhanced release of COX-2-derived constrictor prostaglandins. Arterioscler Thromb Vasc Biol. 2005;25:1610-1616. (Pubitemid 41098929)
13. Erdei N, Bagi Z, Edes I, Kaley G, Koller A. H2O2 increases production of constrictor prostaglandins in smooth muscle leading to enhanced arteriolar tone in type 2 diabetic mice. Am J Physiol Heart Circ Physiol. 2007;292:H649-H656. (Pubitemid 46105228)
14. Vanhoutte PM, Feletou M, Taddei S. Endothelium-dependent contractions in hypertension. Br J Pharmacol. 2005;144:449-458.
15. Feletou M, Vanhoutte PM. Endothelial dysfunction: a multifaceted disorder (The Wiggers Award Lecture). Am J Physiol Heart Circ Physiol. 2006;291:H985-H1002.
16. Orrenius S, Nobel CS, van den Dobbelsteen DJ, Burkitte MJ, Slater AF. Dithiocarbamates and the redox regulation of cell death. Biochem Soc Trans. 1996;24:1032-1038. (Pubitemid 26417965)
17. Li C, Browder W, Kao RL. Early activation of transcription factor NF-kappaB during ischemia in perfused rat heart. Am J Physiol. 1999;276:H543-H552. (Pubitemid 29100623)
18. Iseki A, Kambe F, Okumura K, Niwata S, Yamamoto R, Hayakawa T, et al. Pyrrolidine dithiocarbamate inhibits TNFalpha- dependent activation of NF-kappaB by increasing intracellular copper level in human aortic smooth muscle cells. Biochem Biophys Res Commun. 2000;276:88-92.
19. Ross SD, Kron IL, Gangemi JJ, Shockey KS, Stoler M, Kern JA, et al. Attenuation of lung reperfusion injury after transplantation using an inhibitor of nuclear factor-kappaB. Am J Physiol Lung Cell Mol Physiol. 2000;279:L528-L536.
20. Muller DN, Dechend R, Mervaala EM, Park JK, Schmidt F, Fiebeler A, et al. NF-kappaB inhibition ameliorates angiotensin II-induced inflammatory damage in rats. Hypertension. 2000;35: 193-201. (Pubitemid 30054172)
21. Liu SF, Ye X, Malik AB. Inhibition of NF-kappaB activation by pyrrolidine dithiocarbamate prevents in vivo expression of proinflammatory genes. Circulation. 1999;100:1330-1337. (Pubitemid 29440127)
22. Schreck R, Meier B, Mannel DN, Droge W, Baeuerle PA. Dithiocarbamates as potent inhibitors of nuclear factor kappa B activation in intact cells. J Exp Med. 1992;175:1181-1194.
23. Borrello S, Demple B. NF kappa B-independent transcriptional induction of the human manganous superoxide dismutase gene. Arch Biochem Biopys. 1997;348:289-294. (Pubitemid 28028479)
24. Sawada H, Mitani Y, Maruyama J, Jiang BH, Ikeyama Y, Dida FA, et al. A nuclear factor-kappaB inhibitor pyrrolidine dithiocarbamate ameliorates pulmonary hypertension in rats. Chest. 2007;132:1265-1274. (Pubitemid 47621003)
25. Kagota S, Yamaguchi Y, Nakamura K, Kunitomo M. Altered endothelium-dependent responsiveness in the aortas and renal arteries of Otsuka Long-Evans Tokushima Fatty (OLETF) rats, a model of non-insulin-dependent diabetes mellitus. Gen Pharmacol. 2000;34:201-209. (Pubitemid 41081200)
26. Matsumoto T, Kobayashi T, Kamata K. Mechanisms underlying lysophosphatidylcholine-induced potentiation of vascular contractions in the Otsuka Long-Evans Tokushima Fatty (OLETF) rat aorta. Br J Pharmacol. 2006;149:931-941. (Pubitemid 44851717)
27. Matsumoto T, Kobayashi T, Kamata K. Mechanisms underlying the impaired EDHF-type relaxation response in mesenteric arteries from Otsuka Long-Evans Tokushima Fatty (OLETF) rats. Eur J Pharmacol. 2006;538:132-140.
28. Matsumoto T, Kobayashi T, Wachi H, Seyama Y, Kamata K. Vascular NAD(P)H oxidase mediates endothelial dysfunction in basilar arteries from Otsuka Long-Evans Tokushima Fatty (OLETF) rats. Atherosclerosis. 2007;192:15-24. (Pubitemid 46602302)
29. Matsumoto T, Noguchi E, Ishida K, Kobayashi T, Yamada N, Kamata K. Metformin normalizes endothelial function by suppressing vasoconstrictor prostanoids in mesenteric arteries from OLETF rats, a model of type 2 diabetes. Am J Physiol Heart Circ Physiol. 2008;295:H1165-H1176.
30. Matsumoto T, Kakami M, Noguchi E, Kobayashi T, Kamata K. Imbalance between endothelium-derived relaxing and contracting factors in mesenteric arteries from aged OLETF rats, a model of Type 2 diabetes. Am J Physiol Heart Circ Physiol. 2007;293:H1480-H1490. (Pubitemid 47367192)
31. Matsumoto T, Nakayama N, Ishida K, Kobayashi T, Kamata K. Eicosapentaenoic acid improves imbalance between vasodilator and vasoconstrictor actions of endothelium-derived factors in mesenteric arteries from chronic stage of type 2 diabetic rats. J Pharmacol Exp Ther. 2009;329:324-334.
32. Matsumoto T, Takaoka E, Ishida K, Nakayama N, Kobayashi T, Kamata K. Abnormalities of endothelium-dependent responses in mesenteric arteries from Otsuka Long-Evans Tokushima Fatty (OLETF) rats are improved by chronic treatment with thromboxane A(2) synthase inhibitor. Atherosclerosis. In press.
33. Matsumoto T, Kobayashi T, Kamata K. Alterations in EDHFtype relaxation and phosphodiesterase activity in mesenteric arteries from diabetic rats. Am J Physiol Heart Circ Physiol. 2003;285:H283-H291. (Pubitemid 36736440)
34. Pannirselvam M, Wiehler WB, Anderson T, Triggle CR. Enhanced vascular reactivity of small mesenteric arteries from diabetic mice is associated with enhanced oxidative stress and cyclooxygenase products. Br J Pharmacol. 2005;144:953-960. (Pubitemid 40593021)
35. Bierhaus A, Schiekofer S, Schwaninger M, Andrassy M, Humpert PM, Chen J, et al. Diabetes-associated sustained activation of the transcription factor nuclear factor-kappaB. Diabetes. 2001;50:2792-2808. (Pubitemid 33733131)
36. Kleinbongard P, Dejam A, Lauer T, Jax T, Kerber S, Gharini P, et al. Plasma nitrite concentrations reflect the degree of endothelial dysfunction in humans. Free Radic Biol Med. 2006; 40:295-302. (Pubitemid 43069353)
37. Oelze M, Daiber A, Brandes EP, Hortmann M, Wenzel P, Hink U, et al. Nebivolol inhibits superoxide formation by NADPH oxidase and endothelial dysfunction in angiotensin II-treated rats. Hypertension. 2006;48:677-684. (Pubitemid 44843872)
38. Kawano K, Hirashima T, Mori S, Saitoh Y, Kurosumi M, Natori T. Spontaneous long-term hyperglycemic rat with diabetic complications. Otsuka Long-Evans Tokushima Fatty (OLETF) strain. Diabetes. 1992;41:1422-1428.
39. Sakamoto S, Minami K, Niwa Y, Ohnaka M, Nakaya Y, Mizuno A, et al. Effect of exercise training and food restriction on endothelium-dependent relaxation in the Otsuka Long-Evans Tokushima Fatty rat, a model of spontaneous NIDDM. Diabetes. 1998;47:82-86. (Pubitemid 28030811)
40. Rodriguez-Iturbe B, Ferrebuz A, Vanegas V, Quiroz Y, Mezzano S, Vaziri ND. Early and sustained inhibition of nuclear factor-kappaB prevents hypertension in spontaneously hypertensive rats. J Pharmacol Exp Ther. 2005;315:51-57. (Pubitemid 41380497)
41. Tapia E, Sanchez-Gonzalez DJ, Medina-Campos ON, Soto V, Avila-Casado C, Martinez-Martinez CM, et al. Treatment with pyrrolidine dithiocarbamate improves proteinuria, oxidative stress, and glomerular hypertension in overload proteinuria. Am J Physiol Renal Physiol. 2008;295:F1431-F1439.
42. Helmersson J, Vessby B, Larsson A, Basu S. Association of type 2 diabetes with cyclooxygenase-mediated inflammation and oxidative stress in an elderly population. Circulation. 2004;109: 1729-1734. (Pubitemid 38500674)
43. Natarajan R, Nadler JL. Lipid inflammatory mediators in diabetic vascular disease. Arterioscler Thromb Vasc Biol. 2004; 24:1542-1548. (Pubitemid 39180875)
44. Koller A, Kaley G. Prostaglandins mediate arteriolar dilation to increased blood flow velocity in skeletal muscle microcirculation. Circ Res. 1990;67:529-534. (Pubitemid 20242595)
45. Kobayashi T, Kamata K. Modulation by hydrogen peroxide of noradrenaline-induced contraction in aorta from streptozotocininduced diabetic rat. Eur J Pharmacol. 2002;441:83-89. (Pubitemid 34465693)
46. Pieper GM, Riaz-ul-Haq. Activation of nuclear factor-kappaB in cultured endothelial cells by increased glucose concentration: prevention by calphostin C. J Cardiovasc Pharmacol. 1997;30: 528-532.
47. Nishikawa T, Edelstein D, Du XL, Yamagishi S, Matsumura T, Kaneda Y, et al. Normalizing mitochondrial superoxide production blocks three pathways of hyperglycaemic damage. Nature. 2000;404:787-790. (Pubitemid 30212409)
48. Topping RJ, Jones MM. Optimal dithiocarbamate structure for immunomodulator action. Med Hypotheses. 1988;27:55-57.
49. Barnes PJ, Karin M. Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med. 1997;336:1066-1071. (Pubitemid 27163860)
50. Satriano J, Schlondorff D. Activation and attenuation of transcription factor NF-kB in mouse glomerular mesangial cells in response to tumor necrosis factor-alpha, immunoglobulin G, and adenosine 3':5'-cyclic monophosphate. Evidence for involvement of reactive oxygen species. J Clin Invest. 1994;94: 1629-1636. (Pubitemid 24309886)
51. Schmidt KN, Traenckner EB, Meier B, Baeuerle PA. Induction of oxidative stress by okadaic acid is required for activation of transcription factor NF-kappa B. J Biol Chem. 1995;270:27136-27142.
52. Sowers JR. Insulin resistance and hypertension. Am J Physiol Heart Circ Physiol. 2004;286:H1597-H1602.
53. Elks CM, Mariappan N, Haque M, Guggilam A, Majid DS, Francis J. Chronic NF-{kappa}B blockade reduces cytosolic and mitochondrial oxidative stress and attenuates renal injury and hypertension in SHR. Am J Physiol Renal Physiol. 2009;296:F298-F305.